Yunik-Tech: How Much Runway Do The Warrants And General-Partner Concessions Really Buy
The main article argued that Yunik-Tech is still buying time. This continuation isolates that time-buying mechanism and shows that even after the September 2025 rights issue, the January 2026 raise, and the Series 2 extension, a large part of the bridge still rests on deferred salary and management fees, while full warrant exercise still would not cover the 2026 deferred-payment load on its own.
What The Funding Bridge Really Contains
The main article argued that Yunik-Tech ended 2025 with a stronger portfolio on paper, but with a funding problem that remained unresolved at the public-partnership level. This continuation isolates the more practical question: what exactly made up the bridge that bought the partnership more time, and how deep is that bridge really.
The central conclusion is that the bridge is real, but much shallower than it first appears. In 2025 the partnership did receive a real cash bridge from the rights issue, but at the same time a large share of head-office costs simply did not leave the company in cash. In early 2026 another small funding layer was added, but it was earmarked only for operating needs, while the warrants were given more time. Even in a full-exercise scenario for every outstanding Series 2 warrant, the implied gross proceeds still fall short of the 2026 deferred salary and management-fee burden on their own.
That is the key point. With no credit lines and no loans, there is no hidden financing layer here. The path relies on four ingredients only: concessions by the general partner and management, small equity raises, the hope of warrant exercise, and future realizations out of the portfolio. The first three buy time. None of them solves the funding problem on its own.
| Layer | What actually happened | What it provided | What remains unresolved |
|---|---|---|---|
| General-partner and management concessions | In 2025, $ 329 thousand of salary and management fees were not paid in cash and were recorded as a controlling-shareholder benefit | Immediate relief to cash burn | This is deferral, not new cash. In March 2026 the mechanism was extended into 2027 and includes a possible conversion into units |
| September 2025 rights issue | About $ 543 thousand gross and about $ 496 thousand net, plus 887,776 Series 2 warrants | A real cash bridge into 2025 | The warrant layer was also recorded as a financial liability of $ 60 thousand, rising to $ 95 thousand by year-end |
| January 2026 shelf offering | 188,700 units and 94,350 Series 2 warrants were issued | Another small operating bridge | The proceeds were earmarked for ongoing operations only and not for new target-company investments |
| Series 2 extension | In February 2026 the partnership sought an extension to September 15, 2026, arguing that warrant exercise is a cheaper funding route than a new prospectus raise | More time to try to draw capital through exercise | The mechanism still depends on the unit price and on a tight legal and exchange timetable |
The Concession Layer: Most Salary And Management-Fee Cost Did Not Leave In Cash
Note 12 shows how much of the 2025 bridge began on the cost side rather than the financing side. Salary and related expense came to $ 182 thousand, and management fees to the general partner came to $ 354 thousand. Of that, $ 31 thousand of salary cost and $ 298 thousand of management fees were not actually paid and were instead recorded as a controlling-shareholder benefit. Together, that was $ 329 thousand.
This chart says more than a long paragraph could. Out of $ 536 thousand of combined salary and management-fee cost, more than 61% did not leave in cash. Against total 2025 general and administrative expense, those $ 329 thousand were nearly 39% of the full overhead base. This is not a minor accounting footnote. It is real funding relief created by non-payment.
And it does not stop in 2025. The reduction and deferral mechanism was applied again for 2026, and in a March 2026 update letter it was extended into 2027 as well. By then the condition becomes much tougher: if during 2027 the partnership's cash balance rises to at least NIS 4.604 million, the mechanism stops and the deferred amounts are to be paid, subject to the accumulated balances up to that point being repaid in full. If those conditions are not met, the general partner and management may seek to convert the 2027 accrued deferred amounts into participation units, subject to approvals.
That makes the read quite clear. The support from the general partner is no longer just a one-off waiver. It has become part of the real capital structure. As long as there is no alternative source of cash, the bridge extends runway through deferral. And if the deferral does not turn into cash coverage, it can eventually turn into dilution.
The Warrant Layer: Even Full Exercise Does Not Close 2026 On Its Own
The September 2025 rights issue did provide a real cash bridge. Under Note 9, the partnership raised about $ 543 thousand gross and about $ 496 thousand net, while issuing 1,849,513 participation units and 887,776 Series 2 warrants. But Note 10 is the reminder that warrants are not cash. At first trading the warrant layer was recorded as a financial liability of $ 60 thousand, and by year-end the fair value of that liability had already risen to $ 95 thousand.
So even in the financing layer that already succeeded, there is a distinction between cash that actually came in and an option layer that may or may not become cash later. In January 2026 the partnership added another 94,350 Series 2 warrants, but the shelf offering document made clear that there were no immediate proceeds from those warrants themselves. They only create the possibility of later funding if market conditions allow exercise.
This is the decisive number set in the continuation. The warrant-extension request stated that 982,116 Series 2 warrants were outstanding at the time of the application. At an exercise price of NIS 1.2 per unit, that translates into about NIS 1.179 million of gross potential proceeds if every one of them is exercised. Against that, the January 2026 shelf offering stated that the expected 2026 deferred-payment burden was about NIS 1.129 million of management fees plus NIS 433 thousand of salaries, or roughly NIS 1.562 million in total.
In plain terms, even in a best-case scenario where every Series 2 warrant turns into cash, the gross proceeds would reach only about 75% of the 2026 deferred salary and management-fee burden. And that is before any other operating cost is counted. So the warrant layer is not a full solution. At best it narrows the gap.
January 2026 Was Not A Growth Raise
The key point in the January 14, 2026 shelf offering is not just the small size of the raise. It is what the money was allowed to do. The opening page says the proceeds are meant to fund the partnership's ongoing operations only and will not be directed to new investments in new target companies. Later in the document, the use-of-proceeds section says that the money is for ongoing operating expenses, including deferred payments to the general partner and management.
That changes the whole reading of the move. The market was not funding a new deployment chapter here. It was funding more waiting time. That is why the January 2026 raise belongs inside the funding bridge, not inside the growth case.
The annual report connects the same dots directly. As of the report date the partnership had no credit facilities and no loans, and management's assessment that it had more than 12 months of runway rested explicitly on the reduction in management fees and salary costs as well. Once the partnership itself puts those two things in the same sentence, it is effectively telling readers that the operating bridge and the concessions from the general partner are one story.
The Extension Bought Time, But It Is Still Price-Dependent And Schedule-Dependent
The extension request matters mostly because of what it reveals about the quality of the bridge. In the February 2, 2026 court application, the partnership stated that no Series 2 warrants had been exercised between issuance and the filing date, and that the participation unit was then trading at 120 agorot, leaving no economic incentive to exercise the warrants.
The partnership did not try to hide that logic. It stated plainly that raising capital through warrant exercise is cheaper and more attractive than a prospectus-based raise, which is why it sought a six-month extension to September 15, 2026. That wording matters because it shows that the warrant layer is not being treated as a marginal instrument. It is one of the main remaining financing routes.
But even that route was not automatic. In the HTM clarification published on February 4, 2026, the partnership explained that because March 15, 2026 fell on a Sunday, which was no longer a trading day, the final exercise date moved to March 16, 2026, the last trading day shifted to March 11, 2026, and notice of the change had to reach the exchange by March 10, 2026. So even the act of extending the bridge depended on a very tight court and exchange timetable.
The last piece is still the market price. In the latest market snapshot, dated April 3, 2026, the unit traded at only 102.4 agorot, still below the NIS 1.2 exercise price. So the extension did buy more time, but it did not change the fact that Series 2 remained out of the money.
Bottom Line
The main article argued that Yunik-Tech is buying time. This continuation shows what that time is actually made of: in 2025, $ 329 thousand of salary and management fees that were not paid in cash; in September 2025, a $ 496 thousand net rights raise; in early 2026, a small offering whose cash was ring-fenced for operating needs; and beyond that, the hope that the unit price will eventually allow Series 2 to be exercised.
This is not an accounting quirk. It is the partnership's funding mechanism.
For unit holders, the implication is that the warrants and the general-partner concessions do extend the runway, but they do not remove the need for larger cash realizations out of the portfolio. As long as the unit price remains below NIS 1.2, as long as there are no alternative credit lines, and as long as part of the head-office cost base keeps being deferred instead of being covered in cash, this remains a bridge of time, not a bridge to resolution.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.